Caribou Biosciences, Inc. - CRBU STOCK NEWS

Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, is scheduled to present at two events in June:

1. Jefferies Healthcare Conference in New York, NY on June 7, 2023, at 3:00 pm EDT

2. Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 13, 2023, at 3:20 pm PDT

Both presentations will be available via webcast. Interested parties can access the webcasts through the Events page on Caribou's website. The recordings will remain accessible for 30 days after each event.

Caribou Biosciences (Nasdaq: CRBU) reported Q1 2023 financial results and provided a business update. Key highlights include:

1. CB-010: Dose expansion in ANTLER Phase 1 trial for second-line LBCL patients; dose escalation data expected in H2 2023.

2. CB-011: CaMMouflage Phase 1 trial enrolling r/r MM patients; received Fast Track designation.

3. CB-012: IND application for r/r AML planned for H2 2023.

4. Financial position: $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; runway into 2025.

5. Q1 2023 results: Revenue $3.5 million, R&D expenses $25.7 million, G&A expenses $8.9 million, net loss $28.0 million.

Caribou Biosciences (Nasdaq: CRBU) announced promising preclinical results for CB-012, a CRISPR-edited CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (r/r AML), during the 2023 AACR Annual Meeting. The study indicated CB-012 shows enhanced antitumor activity, prolonged survival in AML xenograft models, and protective immune cloaking against NK cell-mediated cytotoxicity. The therapy is engineered with advanced Cas12a chRDNA technology, enabling five genomic edits for improved efficacy. Caribou plans to submit an IND application for CB-012 in H2 2023, signaling a key step in its clinical development strategy. CEO Rachel Haurwitz stated the data supports advancing CB-012 for clinical trials.

Caribou Biosciences (Nasdaq: CRBU) announced that the FDA has granted Fast Track designation to its investigational therapy, CB-011, for treating relapsed or refractory multiple myeloma (r/r MM). This designation facilitates communication with the FDA during the clinical review process. The CaMMouflage Phase 1 trial, which has recently commenced patient dosing, aims to develop CB-011 as an accessible off-the-shelf treatment option, eliminating the need for lengthy manufacturing and complex procedures. CB-011, derived from Caribou's CAR-T platform, employs advanced genome-editing techniques to enhance antitumor capabilities. The company continues to focus on developing cutting-edge therapies for serious diseases.

Caribou Biosciences (Nasdaq: CRBU) announced the first patient has been dosed in the CaMMouflage Phase 1 trial of CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at patients with relapsed or refractory multiple myeloma. This trial seeks to evaluate the safety and efficacy of the therapy, utilizing an innovative immune cloaking strategy to enhance antitumor activity by mitigating rejection from T and natural killer cells. As part of Caribou's aim to address unmet needs in treatment accessibility, the trial will include adults with extensive prior therapies. The company plans to continue patient enrollment to assess CB-011's therapeutic potential.

Caribou Biosciences, Inc. (Nasdaq: CRBU) announced the start of the dose expansion phase of its CB-010 ANTLER trial for second-line large B cell lymphoma (LBCL) patients. CB-010 is the first allogeneic CAR-T therapy assessed in this setting. The dose escalation was well tolerated, with no dose-limiting toxicities observed at the highest dose level. Earlier cohorts showed promising results, with complete responses in 6 out of 6 patients treated. The trial will evaluate two dose levels on about 30 patients to establish the recommended Phase 2 dose and aims to address the challenges associated with autologous therapies. An update is expected in H2 2023.

Caribou Biosciences (CRBU) reported Q4 and full-year 2022 results, highlighting ongoing progress in its clinical pipeline. As of December 31, 2022, the company held $317 million in cash and equivalents, sufficient to fund operations into 2025. The lead therapy, CB-010, showed promising results in treating relapsed/refractory B-cell non-Hodgkin lymphoma, with notable complete response rates. Recent advancements include the activation of clinical sites for CB-011 and the initiation of IND-enabling studies for CB-012, targeting acute myeloid leukemia. However, a net loss of $99.4 million for 2022 raises concerns.